Economic evaluation of treatments for cancer in childhood

Barr, Ronald D.; Feeny, David; Furlong, William

doi:10.1016/j.ejca.2004.01.033

Cited by 39 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These families reported having to curtail their social/lifestyle activities more than families who lived closer to treatment centers. Lastly, families of children who had extensive treatment times typically were the families who were "most vulnerable to financial distress" (Cohn et al, 2003;854) (Barr et al, 1996;Barr et al, 2004). In a review of the literature, Tsimicalis et al (2006) suggested that costs (time, social participation, ability to work productively) would potentially affect the daily lives of children suffering from cancer.…”

Section: A Chorus Of Voicesmentioning

confidence: 98%

My Child has Cancer: The Costs of Mothers' Experiences of Having a Child with Pediatric Cancer

Fletcher

2010

Issues in Comprehensive Pediatric Nursing

View full text Add to dashboard Cite

These findings exposed the realities of mothers faced with pediatric cancer, and reveal costs incurred by mothers caring for their ailing children, yielding information that can be used as a source of support for those faced with similar situations. Additionally, health care professionals are provided with insight into the costs associated with childhood cancer. This information can be used to help families cope more effectively with cancer and its negative effects.

show abstract

Section: A Chorus Of Voicesmentioning

confidence: 98%

My Child has Cancer: The Costs of Mothers' Experiences of Having a Child with Pediatric Cancer

Fletcher

2010

Issues in Comprehensive Pediatric Nursing

View full text Add to dashboard Cite

show abstract

“…However, none have assessed the economic cost of delivering AML chemotherapy. Comparisons of cost between treatment arms have not been performed for any pediatric cooperative group Phase III clinical trial and are infrequently assessed in adult cooperative group oncology trials . Interpretation of clinical trial outcomes in the context of cost is of significant interest to patients, providers, policy makers, and payers.…”

Section: Introductionmentioning

confidence: 99%

“…Comparisons of cost between treatment arms have not been performed for any pediatric cooperative group Phase III clinical trial and are infrequently assessed in adult cooperative group oncology trials. [7][8][9] Interpretation of clinical trial outcomes in the context of cost is of significant interest to patients, providers, policy makers, and payers. A more complete understanding of the drivers of pediatric AML treatment costs may help to identify effective cost containment strategies and prioritize resources.…”

Section: Introductionmentioning

confidence: 99%

Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group

Getz

Alonzo

et al. 2015

Pediatr Blood Cancer

View full text Add to dashboard Cite

Background A better understanding of drivers of treatment costs may help identify effective cost containment strategies and prioritize resources. We aimed to develop a method for estimating inpatient costs for pediatric patients with acute myeloid leukemia (AML) enrolled on NCI-funded Phase III trials, compare costs between AAML0531 treatment arms (standard chemotherapy ± gemtuzumab ozogamicin (GMTZ)), and evaluate primary drivers of costs for newly diagnosed pediatric AML. Procedure Patients from the AAML0531 trial were matched on hospital, sex, and dates of birth and diagnosis to the Pediatric Health Information Systems (PHIS) database to obtain daily billing data. Inpatient treatment costs were calculated as adjusted charges multiplied by hospital-specific cost-to-charge ratios. Generalized linear models were used to compare costs between treatment arms and courses, and by patient characteristics. Results Inpatient costs did not differ by randomized treatment arm. Costs varied by course with stem cell transplant being most expensive, followed by Intensification II (cytarabine/mitoxantrone) and Induction I (cytarabine/daunorubicin/etoposide). Room/board and pharmacy were the largest contributors to inpatient treatment cost, representing 74% of the total cost. Higher AML risk group (P = 0.0003) and older age (P < 0.0001) were associated with significantly higher daily inpatient cost. Conclusions Costs from external data sources can be successfully integrated into NCI-funded Phase III clinical trials. Inpatient treatment costs did not differ by GMTZ exposure but varied by chemotherapy course. Variation in cost by course was driven by differences in duration of hospitalization through room/board charges as well as increased clinical and pharmacy charges in specific courses. Pediatr Blood Cancer

show abstract

“…A cascade of negative effects of this psychological distress is manifested in parental posttraumatic stress syndrome (PTSS) [6–11] depression, somatization disorders [12], economic burdens [13], and family tensions [14]. Furthermore, in several studies the results indicated that siblings of children with cancer are at risk for emotional, internalizing problems and/or behavioral, externalizing problems [15–21].…”

Section: Introductionmentioning

confidence: 99%

A Systematic Review of Randomized Controlled Interventions for Parents' Distress in Pediatric Leukemia

2011

View full text Add to dashboard Cite

Objective. This review aims to summarize the existing evidence concerning interventions towards reducing stress in parents with a child with leukemia and their effect in child and family wellbeing. Methods. A systematic review strategy was conducted using MEDLINE covering the period January 1980 to June 2010. Results. Seven randomized controlled trials met the inclusion criteria including in total 1045 parents participants. A variety of cognitive-behavioral interventions problem-solving skills training programs have been used for managing distress in parents and children. Outcome measures are assessed by self-report, observer report, behavioral/psychological, and physiological measures. The most prominent methodological problems were the marked heterogeneity in stress measurement and the relative absence of proper measurement and adjustment of moderating and mediating factors. The largest effect has been obtained by combined cognitive-behavioral interventions with promising but limited evidence for several other psychological interventions. Conclusions. Recommendations for future RCTs are provided, and particular attention to the quality of trial design and reporting is highlighted.

show abstract

Economic evaluation of treatments for cancer in childhood

Cited by 39 publications

References 37 publications

My Child has Cancer: The Costs of Mothers' Experiences of Having a Child with Pediatric Cancer

My Child has Cancer: The Costs of Mothers' Experiences of Having a Child with Pediatric Cancer

Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group

A Systematic Review of Randomized Controlled Interventions for Parents' Distress in Pediatric Leukemia

Contact Info

Product

Resources

About